QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atos SE stock logo
AEXAF
Atos
$2.38
$1.79
$16.54
N/AN/A5,393 shs2,000 shs
Affirm Holdings, Inc. stock logo
AFRM
Affirm
$31.05
-0.3%
$36.37
$8.80
$52.48
$9.53B3.579.58 million shs2.37 million shs
Atlas Blockchain Group Inc stock logo
ATLEF
Atlas Blockchain Group
$0.00
$0.00
$0.12
N/AN/A37,255 shs7,400 shs
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$68.49
$68.47
$21.65
$73.02
$4.62B0.452.07 million shs74 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atos SE stock logo
AEXAF
Atos
0.00%+17.54%+15.68%-42.63%-82.34%
Affirm Holdings, Inc. stock logo
AFRM
Affirm
+0.91%-7.84%-8.17%-26.14%+171.11%
Atlas Blockchain Group Inc stock logo
ATLEF
Atlas Blockchain Group
0.00%0.00%0.00%0.00%0.00%
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atos SE stock logo
AEXAF
Atos
0.0641 of 5 stars
0.00.01.70.01.10.01.3
Affirm Holdings, Inc. stock logo
AFRM
Affirm
0.8388 of 5 stars
1.93.00.00.00.93.30.6
Atlas Blockchain Group Inc stock logo
ATLEF
Atlas Blockchain Group
N/AN/AN/AN/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atos SE stock logo
AEXAF
Atos
N/AN/AN/AN/A
Affirm Holdings, Inc. stock logo
AFRM
Affirm
1.83
Reduce$27.86-10.27% Downside
Atlas Blockchain Group Inc stock logo
ATLEF
Atlas Blockchain Group
N/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest GBT, AFRM, ATLEF, and AEXAF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$50.00 ➝ $41.00
4/3/2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold
2/12/2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$44.00 ➝ $47.00
2/9/2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$35.00 ➝ $41.00
2/9/2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderweight ➝ Underweight$6.00 ➝ $16.00
2/9/2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$26.00 ➝ $50.00
2/9/2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$18.00 ➝ $20.00
2/9/2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$24.00 ➝ $35.00
2/9/2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderperform ➝ Underperform$20.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atos SE stock logo
AEXAF
Atos
N/AN/AN/AN/AN/AN/A
Affirm Holdings, Inc. stock logo
AFRM
Affirm
$1.59B6.00N/AN/A$8.54 per share3.64
Atlas Blockchain Group Inc stock logo
ATLEF
Atlas Blockchain Group
N/AN/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$194.75M23.73N/AN/A$3.05 per share22.46

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atos SE stock logo
AEXAF
Atos
N/A$2.210.97N/AN/AN/AN/AN/AN/A
Affirm Holdings, Inc. stock logo
AFRM
Affirm
-$985.34M-$2.49N/AN/AN/A-39.19%-25.10%-7.76%5/8/2024 (Confirmed)
Atlas Blockchain Group Inc stock logo
ATLEF
Atlas Blockchain Group
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/A

Latest GBT, AFRM, ATLEF, and AEXAF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
Affirm Holdings, Inc. stock logo
AFRM
Affirm
-$0.70N/A+$0.70N/AN/AN/A  
2/8/2024Q2 2024
Affirm Holdings, Inc. stock logo
AFRM
Affirm
-$0.28-$0.20+$0.08$0.14$523.92 million$591.11 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atos SE stock logo
AEXAF
Atos
$0.70N/AN/A31.64%N/A
Affirm Holdings, Inc. stock logo
AFRM
Affirm
N/AN/AN/AN/AN/A
Atlas Blockchain Group Inc stock logo
ATLEF
Atlas Blockchain Group
N/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atos SE stock logo
AEXAF
Atos
N/AN/AN/A
Affirm Holdings, Inc. stock logo
AFRM
Affirm
2.35
11.49
11.49
Atlas Blockchain Group Inc stock logo
ATLEF
Atlas Blockchain Group
N/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.92
6.88
6.17

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Atos SE stock logo
AEXAF
Atos
25.91%
Affirm Holdings, Inc. stock logo
AFRM
Affirm
69.29%
Atlas Blockchain Group Inc stock logo
ATLEF
Atlas Blockchain Group
N/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Atos SE stock logo
AEXAF
Atos
N/A
Affirm Holdings, Inc. stock logo
AFRM
Affirm
13.05%
Atlas Blockchain Group Inc stock logo
ATLEF
Atlas Blockchain Group
N/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Atos SE stock logo
AEXAF
Atos
95,140N/AN/ANot Optionable
Affirm Holdings, Inc. stock logo
AFRM
Affirm
2,171306.87 million266.83 millionOptionable
Atlas Blockchain Group Inc stock logo
ATLEF
Atlas Blockchain Group
N/AN/AN/ANot Optionable
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
45767.48 million64.17 millionOptionable

GBT, AFRM, ATLEF, and AEXAF Headlines

SourceHeadline
Executive ProfilesExecutive Profiles
pharmexec.com - April 17 at 12:57 AM
What the Amex GBT-CWT merger means for the travel industryWhat the Amex GBT-CWT merger means for the travel industry
travelweekly-asia.com - March 26 at 7:18 AM
Amex GBT set to acquire CWT for USD 570mnAmex GBT set to acquire CWT for USD 570mn
travelbizmonitor.com - March 26 at 2:18 AM
Amex GBT to purchase CWT for $871mAmex GBT to purchase CWT for $871m
travelweekly.com.au - March 26 at 2:18 AM
Amex GBT to acquire rival CWT in $570m dealAmex GBT to acquire rival CWT in $570m deal
c-mw.net - March 25 at 4:18 PM
Amex GBT acquires its competitor CWTAmex GBT acquires its competitor CWT
fvw.de - March 25 at 9:25 AM
Amex GBT buys rival CWT in $570m dealAmex GBT buys rival CWT in $570m deal
businesstravelnewseurope.com - March 25 at 9:25 AM
Amex GBT to Acquire CWT for $570 MillionAmex GBT to Acquire CWT for $570 Million
skift.com - March 25 at 9:25 AM
How Dr. Ted Love, a cardiologist turned biotech executive, sold his sickle cell company to Pfizer for $5.4BHow Dr. Ted Love, a cardiologist turned biotech executive, sold his sickle cell company to Pfizer for $5.4B
msn.com - March 22 at 4:27 PM
GBT Warns Community of Fraudulent Message CirculationGBT Warns Community of Fraudulent Message Circulation
bossierpress.com - March 18 at 9:38 PM
Global TV Trivia at Blood BrothersGlobal TV Trivia at Blood Brothers
blogto.com - March 7 at 10:00 AM
GBT set to reintroduce National LotteryGBT set to reintroduce National Lottery
dailynews.co.tz - March 7 at 10:00 AM
Volume three of 100 GBT Clinical Cases unveiledVolume three of 100 GBT Clinical Cases unveiled
dentistry.co.uk - February 16 at 9:56 AM
Global Cystic Fibrosis Therapeutics Market Expected to Reach US$ 24.35 Billion by 2028 with a CAGR of 14.40% from 2022Global Cystic Fibrosis Therapeutics Market Expected to Reach US$ 24.35 Billion by 2028 with a CAGR of 14.40% from 2022
medgadget.com - February 15 at 10:37 AM
How Dr. Ted Love Sold Sickle Cell Company To Pfizer For $5.4 BillionHow Dr. Ted Love Sold Sickle Cell Company To Pfizer For $5.4 Billion
forbes.com - February 5 at 3:22 PM
Amex GBT addresses fraud with Expedia Group’s fraud prevention solutionAmex GBT addresses fraud with Expedia Group’s fraud prevention solution
travelweek.ca - February 1 at 1:47 PM
Global Wearable Blood Pressure Monitor Industry Set to Reach US$ 8 Billion by 2032, Fueled by Impressive 15%-16% CAGR | Insights by FMI AnalysisGlobal Wearable Blood Pressure Monitor Industry Set to Reach US$ 8 Billion by 2032, Fueled by Impressive 15%-16% CAGR | Insights by FMI Analysis
fmiblog.com - January 30 at 7:32 PM
Answering the call for excellence with GBTAnswering the call for excellence with GBT
dentistry.co.uk - January 23 at 6:19 AM
Global Brain Tumor Drugs Industry is expected to reach a significant US$ 6.30 Billion by 2033, according to FMI’s forecastGlobal Brain Tumor Drugs Industry is expected to reach a significant US$ 6.30 Billion by 2033, according to FMI’s forecast
fmiblog.com - January 22 at 7:20 AM
GBT Realty to Develop 42,000 SF Shopping Center in Kyle, TexasGBT Realty to Develop 42,000 SF Shopping Center in Kyle, Texas
rebusinessonline.com - January 17 at 4:14 PM
Better Therapeutics, Glooko partner on digital diabetes managementBetter Therapeutics, Glooko partner on digital diabetes management
massdevice.com - January 4 at 6:08 PM
US biotech firm addresses critical gap in blood pressure managementUS biotech firm addresses critical gap in blood pressure management
msn.com - December 27 at 8:55 PM
Should we pay people for donating blood?Should we pay people for donating blood?
bbc.com - December 20 at 1:36 PM
Get on board with GBT for 2024Get on board with GBT for 2024
dentistry.co.uk - December 20 at 8:35 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Atos logo

Atos

OTCMKTS:AEXAF
Atos SE provides digital transformation solutions and services worldwide. It offers advanced computing solutions; analytics, artificial intelligence, and automation solutions; cloud solutions; customer journey analytics and digital customer experience; decarbonization solutions; digital consulting; digital workplace solutions; edge computing and Internet of things solutions; and modern applications and platforms. The company also provides advance detection and response, data protection and governance, digital workplace security, IoT and OT security, trusted digital identities, and cybersecurity solutions; and infrastructure and foundation services. It serves financial services and insurance, healthcare and life sciences, manufacturing, public sector and defense, resources and services, and telecommunication and media industries. The company was incorporated in 1982 and is headquartered in Bezons, France.
Affirm logo

Affirm

NASDAQ:AFRM
Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce in the United States, Canada, and internationally. The company's platform includes point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. Its commerce platform, agreements with originating banks, and capital markets partners enables consumers to pay for a purchase over time with terms ranging up to 60 months. The company has active merchants covering small businesses, large enterprises, direct-to-consumer brands, brick-and-mortar stores, and companies with an omni-channel presence. Its merchants represent a range of industries, including sporting goods and outdoors, furniture and homewares, travel and ticketing, apparel, accessories, consumer electronics, and jewelry. Affirm Holdings, Inc. was founded in 2012 and is headquartered in San Francisco, California.
Atlas Blockchain Group logo

Atlas Blockchain Group

OTCMKTS:ATLEF
Atlas Blockchain Group Inc. validates transactions on the blockchain. The company also provides co-location, back-up/redundancy IT, telecom equipment, and cloud computing services to small and medium size businesses in Western Canada. In addition, it offers software manufacturing rental facilities to IT startup companies. The company was formerly known as Atlas Cloud Enterprises Inc. and changed its name to Atlas Blockchain Group Inc. in July 2018. Atlas Blockchain Group Inc. is headquartered in Vancouver, Canada.
Global Blood Therapeutics logo

Global Blood Therapeutics

NASDAQ:GBT
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.